pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›DAYBUE
drug · small molecule
save

DAYBUE

updated 3mo ago
by $ACAD ACADIA PHARMACEUTICALS INC🔗 ChEMBL
community read0 votes

🐶 often sniffed alongside

top 4
  • drugtrofinetide28 co-mentions · 7 sources
  • tagApproval28 co-mentions · 7 sources
  • drugDAYBUE STIX28 co-mentions · 7 sources
  • tagSmall Molecule14 co-mentions · 7 sources

Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for rett syndrome and 5 investigational indications.

all catalysts(0)

nothing on the calendar yet

Trials studying DAYBUE

  • phase3Open-Label Extension Study of Trofinetide for Rett Syndrometerminatedn=77
  • phase3An Open-Label Study of Trofinetide for the Treatment of Girls Two to Five Years of Age Who Have Rett Syndrometerminatedn=15
  • phase3Open-Label Extension Study of Trofinetide for the Treatment of Girls and Women With Rett Syndromecompletedn=154
  • phase3Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome (LAVENDER™)completedn=187

News(1)

  • On second try, Acadia drug gets nod from European regulators
    The influential CHMP committee also threw its support behind more than a dozen other medicines while recommending the marketing authorization for Tavneos be revoked.
    biopharma_dive · 1mo ago
brand
DAYBUE
trade names
Daybue
generic
TROFINETIDE
MOA
12.1 Mechanism of Action The mechanism by which trofinetide exerts therapeutic effects in patients with Rett syndrome is unknown.
indication
1 INDICATIONS AND USAGE DAYBUE and DAYBUE STIX are indicated for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older. DAYBUE and DAYBUE STIX are indicated for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older. ( 1 )
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 13m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?